Overly broad definitions, a lack of appropriate, or any, comparison groups, among other things, in studies looking at the incidence, prevalence, and control of the condition-;epidemiology-;have distorted the risks, say the researchers.
New Pluvicto data point to a potential wider indication, but Novartis leaves regulatory timeline up in the air: #ESMO23
MADRID — Novartis’ radiopharmaceutical drug Pluvicto staved off prostate cancer progression for a median of six months longer than hormone therapy in a pivotal study,
October 24, 2023